Coronary Thrombosis in a Patient with COVID-19 Who Was on Anticoagulant Therapy

Mohammad Reza Hatamnejad; Farima Fallah Tafti; Ali Abdi ardekani; Shahrokh Sadeghi Boogar; Hamed Bazrafshan Drissi

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

Authors Guide Submit Manuscript

Coronary Thrombosis in a Patient with COVID-19 Who Was on Anticoagulant Therapy

Authors:

Mohammad Reza Hatamnejad

¹,

Farima Fallah Tafti¹,

Ali Abdi ardekani²,

Shahrokh Sadeghi Boogar

³,

Hamed Bazrafshan Drissi

^2,*

1Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran

2Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

3Department of Internal Medicine, Shiraz University of Medical Science, Shiraz, IR Iran

International Cardiovascular Research Journal:Vol. 15, issue 3; e114520

Published online:Sep 01, 2021

Article type:Case Report

Received:Mar 09, 2021

Accepted:Jul 06, 2021

How to Cite:Mohammad Reza HatamnejadFarima Fallah TaftiAli Abdi ardekaniShahrokh Sadeghi BoogarHamed Bazrafshan DrissiCoronary Thrombosis in a Patient with COVID-19 Who Was on Anticoagulant Therapy.15(3):e114520.

Abstract

Introduction: COVID-19-related thrombotic events are associated with an increase in the risk of mortality and morbidity. Considering the research on the pathophysiology of the disease, the significance of cardiac thrombosis is being more recognized.
Case Presentation: This study aimed to present the first case report of a Left Main Coronary Artery (LMCA) thrombosis due to COVID-19 infection in a middle-aged male with a mechanical valve on anticoagulant therapy and with an International Normalized Ratio (INR) within the therapeutic range.
Conclusions: The results suggested that the therapeutic INR range may need to be higher (about 3.5) during the acute phase of COVID-19 infection to prevent thrombotic events amongst patients with COVID-19 who are on anticoagulant therapy. However, further evidence is required to determine the target range for INR in patients with COVID-19 who are on anticoagulants prior to infection.

Keywords

COVID-19

Coronary Thrombosis

Anticoagulant Drugs

International Normalized Ratio

Fulltext

The full-text is available in pdf.

References

1.
The references are available in pdf.

comments

Leave a comment here

Import into EndNote Import into BibTex

Indexed in

Scopus

Share on

Comments

Number of Comments:0

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Mohammad Reza Hatamnejad:[PubMed][Scholar]
Farima Fallah Tafti:[PubMed][Scholar]
Ali Abdi ardekani:[PubMed][Scholar]
Shahrokh Sadeghi Boogar:[PubMed][Scholar]
Hamed Bazrafshan Drissi:[PubMed][Scholar]